Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis

Cyclophosphamide, bortezomib, and dexamethasone (CyBorD) is highly effective in multiple myeloma. We treated patients with light chain amyloidosis (AL) before stem cell transplantation (ASCT), instead of ASCT in ineligible patients or as salvage. Treatment was a combination of bortezomib (1.5 mg/m(2...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Mikhael, Joseph R., Schuster, Steven R., Jimenez-Zepeda, Victor H., Bello, Nancy, Spong, Jacy, Reeder, Craig B., Stewart, A. Keith, Bergsagel, P. Leif, Fonseca, Rafael
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2012
Предметы:
Clinical Trials and Observations
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3557400/
https://ncbi.nlm.nih.gov/pubmed/22331188
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-11-390930
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы